top of page
Bad Bugs Global Challenge

The prevalence of Vector-Borne Diseases worldwide presents significant challenges for effective health management and treatment in clinics, resulting in various health issues. These bugs, acting as intermediate hosts for harmful bacteria and viruses (such as dengue, malaria, the Zika virus, Lyme disease, and various others) or carrying health risks themselves, can have detrimental effects on individuals. At Deep Knowledge Group, we understand the seriousness of this problem and possess the expertise required to address and mitigate its consequences.

In our quest to combat these health risks, we embrace advanced treatment methods. This innovative approach, in collaboration with advanced clinics and leading experts, provides us with unique capabilities to alleviate the burden of harmful bugs. Our primary objective is to curb the impact of these pervasive health risks and minimize their long-term implications. We welcome investors and partners to join us in this innovative approach to tackling this pressing global issue. Together, we can influence the trajectory of events and contribute to more effective management of health challenges associated with harmful bugs in modern medicine.

Global Perspective

The prevalence of Vector-Borne Diseases has a profound impact on individuals, families, and communities globally, creating a significant public health challenge that extends beyond borders and cultural contexts. As our world faces an increasing prevalence of these health risks, it has become crucial to address the impact of bugs that act as intermediate hosts for harmful bacteria or pose health risks themselves. The adverse effects of these bugs are widespread, impacting millions of people around the world. Understanding the factors influencing the prevalence of these harmful bugs is essential for effective prevention, diagnosis, and management. In the face of this growing challenge, it is imperative to unite efforts and resources to develop innovative solutions that can mitigate the consequences of these health threats and protect the well-being of communities worldwide.

The health risks posed by some harmful bugs like mosquitoes transferring malaria are well-known but the risks of many other harmful bugs are often neglected. This oversight is a growing global concern that demands attention. It's crucial to shift focus towards acknowledging and addressing the profound consequences of harmful bugs on a global scale. By raising awareness and fostering collaboration, we can work towards making the mitigation of these health threats a top global health priority for a healthier and safer world.

Percent of People Affected by Vector-Borne Diseases

Bad Bugs, Lyme Disease and Human Health: Exploring Connection 

One of Vector-Borne Disease that carry Persistent Borrelia cysts, causing Lyme, may reawaken with aging, potentially influencing Alzheimer's progression and some forms of Autism. Recent research discovered Lyme Borrelia DNA in postmortem Alzheimer's brains, suggesting a potential link between these diseases. IHHT-MITOPRO provides a practical strategy to prevent latent Lyme Borreliosis, preserving immune system effectiveness.

Understanding these potential links between Lyme disease, Autism and Alzheimer's is crucial for comprehensive health management and emphasizes the importance of early intervention strategies. 


Clinic Trials 


Top Clinics




Data Points 

Якорь 1

Bad Bugs Related Expenditures Market

The "Bad Bugs Global Challenge Ecosystem" represents the ongoing battle against Vector-Borne Diseases threatening agriculture, public health, and ecosystems worldwide. Annual global agricultural losses due to pests exceed $220 billion, while disease-carrying vectors like mosquitoes cause widespread health concerns, costing billions in healthcare expenses.

The "Harmful Bugs Related Expenditures Market" is a vital economic sector dedicated to combating these threats. With an annual expenditure of $70 billion globally, it offers a range of products and services such as insecticides and innovative technologies. This market reflects a growing recognition of the need for effective pest management strategies and a shift towards sustainable solutions amid environmental concerns and regulatory pressures.

Bad Bugs Challenge
Ecosystem Dashboard

The Bad Bugs Challenge Ecosystem Dashboard is a centralized hub designed to meet all the market and business intelligence needs of its users. It offers comprehensive support, encompassing benchmarking for companies, technologies, and thorough competitive and SWOT analysis for over 400 clinics, 3300+ clinical trials, 3000+ investors, and 35,000+ data inputs within the Bad Bugs sector.

Screen Shot 2024-04-30 at 3.33.52 PM.png

Bad Bugs Challenge
Patient Logistic Pathway

Explore the comprehensive journey of individuals affected by harmful bugs through the interactive Bad Bugs Challenge Patient Logistic Pathway. Each stage offers a concise overview, and by selecting individual stages, you can delve into detailed descriptions that provide insights into AI-driven diagnostic, treatment, and management processes tailored specifically to combating these pests. All buttons on this visualization are interactive, allowing you to click on each one to access detailed information.

Bad Bugs Clinical Trials

This map shows the best estimation at what countries trials of Vector-Borne Diseases are conducted. If locations of trials are known definitively, only these locations are counted (but not locations of collaborators and sponsors). If location of a trial is not known exactly, we assume that country of the trial coincides with country of its collaborators.


Each trial can add only one point to a country, even if the trial is conducted in several locations in the country or by several organizations inside one country. Locations of some trials can not be determined from available databases: usually they are conducted by international organizations in the absence of clarifying information. Such trials don't affect the map.


The United States stands as the primary research center for Vector-Borne Diseases clinical trials, hosting 11.1% of identified studies. Africa is a location of conduction of very many studies: Kenya, Burkina Faso, Uganda, Tanzania and Mali hold from 5.1% to 4.3% of trials each. Thailand has 4.1% and UK has 3.8% identified clinical trials.

After 2018, the annual number of clinical trials more than doubled increasing to 2000 studies per year. The jump in clinical trials after 2017 signals a rising awareness of Bad Bugs significance.

Якорь 3

Read More


Screen Shot 2024-05-03 at 3.44.52 PM.png
Coming Soon

One Pager

Screen Shot 2024-05-03 at 3.48.02 PM.png

Strategic Partner Projects


Lyme Disease

Global Pandemia


Autism Global

Challenge Ecosystem


Alzheimer's Global

Challenge Ecosystem